Shinta Oktya Wardhani, - and Jonny Karunia Fajar, - and Laksmi Wulandari, - and Gatot Soegiarto, - and Yeni Purnamasari, - and Anisa Asmiragani, - and Helnida Anggun Maliga, - and Muhammad Ilmawan, - and Gloriana Seran, - and Dheka Sapti Iskandar, - and Conchita Emiliana Ndapa, - and Viviana Hamat, - and Rafika Ajeng Wahyuni, - and Linda Oktaviana Suci Cyntia, - and Feronika Maryanti Maarang, - and Yosef Andrian Beo, - and Olivera Agnes Adar, - and Iraky Mardya Rakhmadhan, - and Emilia Tiara Shantikaratri, - and Ayu Sekarani Damana Putri, - and Rizqa Wahdini, - and Endang Pati Broto, - and Agnes Wanda Suwanto, - and Fredo Tamara, - and Aditya Indra Mahendra, - and Eden Suryoiman Winoto, - and Pratista Adi Krisna, - and Harapan, - (2021) Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis [version 3; peer review: 2 approved]. F1000Research, 10 (64). pp. 1-18. ISSN 20461402

	Text (Peer Review) Karil Artikel 18.pdf Download (658kB)
	Text (Similarity) 2. TURNITIN_Artikel 18.pdf Download (2MB)
	Text (Artikel) 1. Full Text_Artikel 18.pdf Download (5MB)
	Text (Peer Review) 1.Karil_18.pdf Download (360kB)
	Text (Bukti Korespondensi) 4. Korespondensi_18.pdf Download (1MB)

Abstract

Background: Convalescent plasma (CCP) has been used for treating some infectious diseases; however, the efficacy of CCP in coronavirus disease 2019 (COVID-19) remains controversial. The aim of this research was to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. Methods: Embase, PubMed, Web of Science, Cochrane and MedRix were searched for potentially relevant articles. All included papers were assessed for the quality using modified Jadad scale and Newcastle-Ottawa scale for randomized controlled trial (RCT) and non – RCT, respectively. We used a Q test and Egger test to assess the heterogeneity and publication bias among studies, respectively. Mortality rates between patients treated with standard treatment and standard treatment with CCP were compared using a Z test. Results: A total of 12 papers consisting of three cross-sectional studies, one prospective study, five retrospective studies, and three RCT studies were included in our analysis. Of them, a total of 1,937 patients treated with CCP and 3,405 patients without CCP were included. The risk of mortality was 1.92-fold higher in patients without CCP compared to patients treated with CCP (OR: 1.92; 95%CI: 1.33, 2.77; p=0.0005). In severe COVID-19 sub-group analysis, we found that patients without CCP had a 1.32 times higher risk of mortality than those treated with CCP (OR: 1.32; 95%CI: 1.09, 1.60; p=0.0040). Conclusions: CCP, as adjunctive therapy, could reduce the mortality rate among COVID-19 patients.

Actions (login required)

View Item